State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors

Oni J. Blackstock, Karen H. Wang, David A. Fiellin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND: In the United States, mortality from cardiovascular disease has become increasingly common among HIV-infected persons. One-third of HIV-infected persons in care may rely on state-run AIDS Drug Assistance Programs (ADAPs) for cardiovascular disease-related prescription drugs. There is no federal mandate regarding ADAP coverage for non-HIV medications. OBJECTIVE: To assess the consistency of ADAP coverage for type 2 diabetes, hypertension, hyperlipidemia, and smoking cessation using clinical guidelines as the standard of care. DESIGN: Cross-sectional survey of 53 state and territorial ADAP formularies. MAIN MEASURES: ADAPs covering all first-line drugs for a cardiovascular risk factor were categorized as "consistent" with guidelines, while ADAPs covering at least one first-line drug, but not all, for a cardiovascular risk factor, were categorized as "partially consistent". ADAPs without coverage were categorized as "no coverage". KEY RESULTS: Of 53 ADAPs, four (7.5%) provided coverage consistent with guidelines (coverage for all first-line drugs) for all four cardiovascular risk factors. Thirteen (24.5%) provided no coverage for all four risk factors. Thirty-six (68%) provided at least partially consistent coverage for at least one surveyed risk factor. State ADAPs provided coverage consistent with guidelines most frequently for type 2 diabetes (28%), followed by hypertension (25%), hyperlipidemia (15%) and smoking cessation (8%). Statins (66%) were most commonly covered and nicotine replacement therapies (9%) least often. Many ADAPs provided no first-line treatment coverage for hypertension (60%), type 2 diabetes (51%), smoking cessation (45%), and hyperlipidemia (32%). CONCLUSIONS: Consistency of ADAP coverage with guidelines for the surveyed cardiovascular risk factors varies widely. Given the increasing lifespan of HIV-infected persons and restricted ADAP budgets, we recommend ADAP coverage be consistent with guidelines for cardiovascular risk factors.

Original languageEnglish (US)
Pages (from-to)1426-1433
Number of pages8
JournalJournal of General Internal Medicine
Volume26
Issue number12
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

Anti-HIV Agents
Prescription Drugs
Guidelines
Smoking Cessation
Hyperlipidemias
Type 2 Diabetes Mellitus
HIV
Hypertension
Cardiovascular Diseases
Formularies
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiovascular Agents
Budgets
Standard of Care
Nicotine
Pharmaceutical Preparations

Keywords

  • AIDS
  • AIDS drug assistance program
  • cardiovascular disease
  • HIV
  • public assistance

ASJC Scopus subject areas

  • Internal Medicine

Cite this

State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors. / Blackstock, Oni J.; Wang, Karen H.; Fiellin, David A.

In: Journal of General Internal Medicine, Vol. 26, No. 12, 12.2011, p. 1426-1433.

Research output: Contribution to journalArticle

Blackstock, Oni J. ; Wang, Karen H. ; Fiellin, David A. / State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors. In: Journal of General Internal Medicine. 2011 ; Vol. 26, No. 12. pp. 1426-1433.
@article{c672cd521c3e4ca3865506df2f666e9d,
title = "State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors",
abstract = "BACKGROUND: In the United States, mortality from cardiovascular disease has become increasingly common among HIV-infected persons. One-third of HIV-infected persons in care may rely on state-run AIDS Drug Assistance Programs (ADAPs) for cardiovascular disease-related prescription drugs. There is no federal mandate regarding ADAP coverage for non-HIV medications. OBJECTIVE: To assess the consistency of ADAP coverage for type 2 diabetes, hypertension, hyperlipidemia, and smoking cessation using clinical guidelines as the standard of care. DESIGN: Cross-sectional survey of 53 state and territorial ADAP formularies. MAIN MEASURES: ADAPs covering all first-line drugs for a cardiovascular risk factor were categorized as {"}consistent{"} with guidelines, while ADAPs covering at least one first-line drug, but not all, for a cardiovascular risk factor, were categorized as {"}partially consistent{"}. ADAPs without coverage were categorized as {"}no coverage{"}. KEY RESULTS: Of 53 ADAPs, four (7.5{\%}) provided coverage consistent with guidelines (coverage for all first-line drugs) for all four cardiovascular risk factors. Thirteen (24.5{\%}) provided no coverage for all four risk factors. Thirty-six (68{\%}) provided at least partially consistent coverage for at least one surveyed risk factor. State ADAPs provided coverage consistent with guidelines most frequently for type 2 diabetes (28{\%}), followed by hypertension (25{\%}), hyperlipidemia (15{\%}) and smoking cessation (8{\%}). Statins (66{\%}) were most commonly covered and nicotine replacement therapies (9{\%}) least often. Many ADAPs provided no first-line treatment coverage for hypertension (60{\%}), type 2 diabetes (51{\%}), smoking cessation (45{\%}), and hyperlipidemia (32{\%}). CONCLUSIONS: Consistency of ADAP coverage with guidelines for the surveyed cardiovascular risk factors varies widely. Given the increasing lifespan of HIV-infected persons and restricted ADAP budgets, we recommend ADAP coverage be consistent with guidelines for cardiovascular risk factors.",
keywords = "AIDS, AIDS drug assistance program, cardiovascular disease, HIV, public assistance",
author = "Blackstock, {Oni J.} and Wang, {Karen H.} and Fiellin, {David A.}",
year = "2011",
month = "12",
doi = "10.1007/s11606-011-1807-5",
language = "English (US)",
volume = "26",
pages = "1426--1433",
journal = "Journal of General Internal Medicine",
issn = "0884-8734",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors

AU - Blackstock, Oni J.

AU - Wang, Karen H.

AU - Fiellin, David A.

PY - 2011/12

Y1 - 2011/12

N2 - BACKGROUND: In the United States, mortality from cardiovascular disease has become increasingly common among HIV-infected persons. One-third of HIV-infected persons in care may rely on state-run AIDS Drug Assistance Programs (ADAPs) for cardiovascular disease-related prescription drugs. There is no federal mandate regarding ADAP coverage for non-HIV medications. OBJECTIVE: To assess the consistency of ADAP coverage for type 2 diabetes, hypertension, hyperlipidemia, and smoking cessation using clinical guidelines as the standard of care. DESIGN: Cross-sectional survey of 53 state and territorial ADAP formularies. MAIN MEASURES: ADAPs covering all first-line drugs for a cardiovascular risk factor were categorized as "consistent" with guidelines, while ADAPs covering at least one first-line drug, but not all, for a cardiovascular risk factor, were categorized as "partially consistent". ADAPs without coverage were categorized as "no coverage". KEY RESULTS: Of 53 ADAPs, four (7.5%) provided coverage consistent with guidelines (coverage for all first-line drugs) for all four cardiovascular risk factors. Thirteen (24.5%) provided no coverage for all four risk factors. Thirty-six (68%) provided at least partially consistent coverage for at least one surveyed risk factor. State ADAPs provided coverage consistent with guidelines most frequently for type 2 diabetes (28%), followed by hypertension (25%), hyperlipidemia (15%) and smoking cessation (8%). Statins (66%) were most commonly covered and nicotine replacement therapies (9%) least often. Many ADAPs provided no first-line treatment coverage for hypertension (60%), type 2 diabetes (51%), smoking cessation (45%), and hyperlipidemia (32%). CONCLUSIONS: Consistency of ADAP coverage with guidelines for the surveyed cardiovascular risk factors varies widely. Given the increasing lifespan of HIV-infected persons and restricted ADAP budgets, we recommend ADAP coverage be consistent with guidelines for cardiovascular risk factors.

AB - BACKGROUND: In the United States, mortality from cardiovascular disease has become increasingly common among HIV-infected persons. One-third of HIV-infected persons in care may rely on state-run AIDS Drug Assistance Programs (ADAPs) for cardiovascular disease-related prescription drugs. There is no federal mandate regarding ADAP coverage for non-HIV medications. OBJECTIVE: To assess the consistency of ADAP coverage for type 2 diabetes, hypertension, hyperlipidemia, and smoking cessation using clinical guidelines as the standard of care. DESIGN: Cross-sectional survey of 53 state and territorial ADAP formularies. MAIN MEASURES: ADAPs covering all first-line drugs for a cardiovascular risk factor were categorized as "consistent" with guidelines, while ADAPs covering at least one first-line drug, but not all, for a cardiovascular risk factor, were categorized as "partially consistent". ADAPs without coverage were categorized as "no coverage". KEY RESULTS: Of 53 ADAPs, four (7.5%) provided coverage consistent with guidelines (coverage for all first-line drugs) for all four cardiovascular risk factors. Thirteen (24.5%) provided no coverage for all four risk factors. Thirty-six (68%) provided at least partially consistent coverage for at least one surveyed risk factor. State ADAPs provided coverage consistent with guidelines most frequently for type 2 diabetes (28%), followed by hypertension (25%), hyperlipidemia (15%) and smoking cessation (8%). Statins (66%) were most commonly covered and nicotine replacement therapies (9%) least often. Many ADAPs provided no first-line treatment coverage for hypertension (60%), type 2 diabetes (51%), smoking cessation (45%), and hyperlipidemia (32%). CONCLUSIONS: Consistency of ADAP coverage with guidelines for the surveyed cardiovascular risk factors varies widely. Given the increasing lifespan of HIV-infected persons and restricted ADAP budgets, we recommend ADAP coverage be consistent with guidelines for cardiovascular risk factors.

KW - AIDS

KW - AIDS drug assistance program

KW - cardiovascular disease

KW - HIV

KW - public assistance

UR - http://www.scopus.com/inward/record.url?scp=83655167317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83655167317&partnerID=8YFLogxK

U2 - 10.1007/s11606-011-1807-5

DO - 10.1007/s11606-011-1807-5

M3 - Article

VL - 26

SP - 1426

EP - 1433

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

SN - 0884-8734

IS - 12

ER -